Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for 2020 - a successful year marked by outstanding clinical data
Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020.
Business highlights
Positive results in the Phase 3 program of daridorexant, demonstrating improved overall sleep and daytime functioning of patients with insomnia
Daridorexant new drug application (NDA) submitted to the US FDA on January 8, 2021
Positive results in the Japanese registration program for clazosentan, demonstrating reduction in vasospasm-related morbidity and all-cause mortality
US commercial operations established, with leadership team in place, and Syneos Health selected as commercialization partner to build the salesforce for the launch of daridorexant in the US